Why HOLD?
See Bull/Bear case, catalysts, and full risk analysis
See why ($2.99)
Money back if you are not satisfied
Summary
1.
Sentiment remains broadly positive around the CS014 update (often framed as a “game-changer” in investor discussions), but the overall tone is still somewhat cautious ahead of upcoming CS1 readouts; net sentiment is roughly unchanged.
2.
Investeringscaset stärks av operationella framsteg i CS1 (EAP-avslut), men den breddade strategin för CS014 innebär en längre väntan på nästa kliniska fas för den kandidaten. Marknaden avvaktar nu de initiala EAP-resultaten och den faktiska studiestarten för Fas IIb i CS1 under Q2.
3.
Bull case: Kort sikt (1-3 mån):
- **FDA-momentum** efter godkänd studiedesign för Phase IIb-studien med CS1.
- Kommande **Kapitalmarknadsdag** (5 feb) och datapresentationer vid PVRI-kongressen kan agera triggers.
- Säkrad finansiering minskar den omedelbara oron för likviditetsbrist.
Latest news
Since 2026-03-16, Cereno (2026-03-17) received Swedish MPA approval to initiate a pharmacokinetic Phase I study for CS014. The company has also aligned the study design with the FDA, enabling use of valproic acid as a reference and potentially removing the need for additional safety studies and a traditional Phase IIa, implying meaningful time and cost savings. Edison published updates (19 and 23 March) highlighting the faster regulatory path and maintaining a positive view.